HOME >> MEDICINE >> NEWS
SCAI Hildner Lecture highlights innovative techniques for plaque imaging

a picture of the plaque, whereas optical computed tomography uses light to define its structure. Thermography relies on differences in temperature to identify inflamed, vulnerable plaque, while spectroscopy defines its chemical composition, and palpography measures stress on the plaque's thin, fragile cap.

Studies are under way to determine which, if any, of these techniques can best detect and characterize vulnerable plaque. If the studies are positive, plaque imaging could help tens of millions of people with undiagnosed coronary artery disease.

"These techniques could have major societal implications," Dr. Stone said. "Everyone who is prone to cardiovascular disease--virtually all middle-aged and elderly men and postmenopausal women--could benefit from early detection and treatment."


'"/>

Contact: Kathy Boyd David
jdavid62@juno.com
717-422-1181
Society for Cardiovascular Angiography and Interventions
12-May-2006


Page: 1 2

Related medicine news :

1. SCAIS Hildner Lecture traces progress through 30 years of interventional cardiology
2. SCAI Founders Lecture highlights remarkable progress in catheter-based aortic valve replacement
3. William OBrien, Jr., PhD, receives the 2007 AIUM William J. Fry Memorial Lecture Award
4. Lectures, Keynoters, Symposia highlight International Dental Research meeting
5. SCAI Founders Lecture traces impressive progress in interventional cardiology
6. Leading genomic technology expert to present Dickson Prize Lecture at Pitt
7. Richard A. Meyer, MD, receives the 2005 AIUM William J. Fry Memorial Lecture Award
8. NYU Child Study Center presents third Annual Adam Katz Memorial Lecture series
9. UPenn receives 2005 Templeton Research Lectures Grant
10. Research highlights from Thoracic Society Conference
11. SCAI highlights study using wireless technology to speed care of heart attack patients

Post Your Comments:
(Date:5/21/2013)... Dubuque, IA (PRWEB) May 21, 2013 Nearly ... took time out of an award trip in Los Cabos, ... Dia, a “day house” for the elderly. , The facility ... elderly residents of San Jose del Cabo, Mexico. , Platinum ... project began while reflecting on the company’s history. , “Platinum ...
(Date:5/21/2013)... Everspark Interactive, one of the city's leading ... over the past year – and announced another milestone ... marketing efforts for Kids II, a designer of innovative ... a local effort, specializing in search engine optimization (SEO) ... company's website. The company now offers a host of ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Workplace ... world’s leading work-life services provider, and Mayo Clinic ... wellness services. In an initiative set to launch ... Clinic’s coaching model into its existing suite of ... Clinic’s current commercial client base in addition to ...
(Date:5/21/2013)... AAG Health, the leading age management and hormone ... has acquired the OligoScan test made by leading European ... technology, the OligoScan device is capable of measuring in ... metals, 20 trace elements (minerals), and oxidative stress levels. ... as mercury, lead, aluminum, and arsenic, will make it ...
(Date:5/21/2013)... Thousands of Americans, many of them smokers or ... chronic obstructive pulmonary disease (COPD). Now a new ... antibiotic azithromycin may be able to cut down ... "Given that exacerbations of COPD can be ... Victoria Richards, assistant professor of medical science at ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Everspark Named Interactive Marketing Company for Kids II 2Health News:Workplace Options and Mayo Clinic Announce Strategic Relationship 2Health News:Workplace Options and Mayo Clinic Announce Strategic Relationship 3Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 2Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 3Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3
(Date:5/21/2013)... May 21, 2013  Lehigh Valley Health Network has ... devices, adding to its existing arsenal of five ... up residence within the network, LVHN is now deploying ... proactively combat superbugs and provide the best possible patient ... Ultraviolet Disinfector, TRU-D – the signature product of ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ("BRT" ... company focused on developing stem cell based therapies for ... , its President and CEO, will be presenting ... conference will be held on Thursday, May 30, 2013 ... 42nd Street in New York City.  Mr. Weinreb,s presentation ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: